Clinical Trial Update: PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating secukinumab 300 mg for efficacy and safety in patients with lichen planus, completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Lichen Planus
• Lichen Planopilaris
• Lichen Planus
• Mucosal Lichen Planus

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris | Phase 2 | Status: COMPLETED | Results posted: 2023-08-22